ZA200803488B - GLP-1 (Glucagon-like peptide-1) fusion polypeptides with increased peptidase resistance - Google Patents
GLP-1 (Glucagon-like peptide-1) fusion polypeptides with increased peptidase resistanceInfo
- Publication number
- ZA200803488B ZA200803488B ZA200803488A ZA200803488A ZA200803488B ZA 200803488 B ZA200803488 B ZA 200803488B ZA 200803488 A ZA200803488 A ZA 200803488A ZA 200803488 A ZA200803488 A ZA 200803488A ZA 200803488 B ZA200803488 B ZA 200803488B
- Authority
- ZA
- South Africa
- Prior art keywords
- glp
- peptide
- component
- sequence
- glucagon
- Prior art date
Links
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 title abstract 6
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title abstract 6
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 6
- 230000004927 fusion Effects 0.000 title abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 title 2
- 102000035195 Peptidases Human genes 0.000 title 1
- 108091005804 Peptidases Proteins 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 235000019833 protease Nutrition 0.000 title 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 abstract 1
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 abstract 1
- 102400000326 Glucagon-like peptide 2 Human genes 0.000 abstract 1
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 208000034615 apoptosis-related disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05020718A EP1767545B1 (fr) | 2005-09-22 | 2005-09-22 | Polypeptides de fusion de glp-1 (peptide 1 de type glucagon) ayant une resistance accrue a la peptidase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200803488B true ZA200803488B (en) | 2009-10-28 |
Family
ID=35700191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200803488A ZA200803488B (en) | 2005-09-22 | 2006-09-22 | GLP-1 (Glucagon-like peptide-1) fusion polypeptides with increased peptidase resistance |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US8431533B2 (fr) |
| EP (5) | EP1767545B1 (fr) |
| JP (2) | JP5222729B2 (fr) |
| KR (1) | KR20080064840A (fr) |
| CN (1) | CN101273058A (fr) |
| AT (1) | ATE448247T1 (fr) |
| AU (1) | AU2006299134B2 (fr) |
| BR (1) | BRPI0616107A2 (fr) |
| CA (1) | CA2619053A1 (fr) |
| CY (1) | CY1109778T1 (fr) |
| DE (1) | DE602005017628D1 (fr) |
| DK (1) | DK1767545T3 (fr) |
| EA (1) | EA013796B1 (fr) |
| ES (3) | ES2336575T3 (fr) |
| HR (1) | HRP20100062T1 (fr) |
| IL (1) | IL188904A0 (fr) |
| PL (1) | PL1767545T3 (fr) |
| PT (1) | PT1767545E (fr) |
| RS (1) | RS51319B (fr) |
| SG (1) | SG165414A1 (fr) |
| SI (1) | SI1767545T1 (fr) |
| WO (1) | WO2007039140A1 (fr) |
| ZA (1) | ZA200803488B (fr) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1767545B1 (fr) | 2005-09-22 | 2009-11-11 | Biocompatibles UK Limited | Polypeptides de fusion de glp-1 (peptide 1 de type glucagon) ayant une resistance accrue a la peptidase |
| US20100021480A1 (en) * | 2005-10-27 | 2010-01-28 | Peptron Co., Ltd | Bioactive substance-blood protein conjugate and stabilization of a bioactive substance using the same |
| US20130172274A1 (en) | 2005-12-20 | 2013-07-04 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
| US8841255B2 (en) | 2005-12-20 | 2014-09-23 | Duke University | Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides |
| US8178495B2 (en) | 2008-06-27 | 2012-05-15 | Duke University | Therapeutic agents comprising a GLP-1 receptor agonist and elastin-like peptide |
| EP1854455B1 (fr) | 2006-05-10 | 2009-10-07 | Biocompatibles UK Limited | Microcapsules sphériques contenant des peptides du type GLP-1, leur production et leur utilisation |
| EP1972349A1 (fr) * | 2007-03-21 | 2008-09-24 | Biocompatibles UK Limited | Peptides à fusion GLP-1 associée à un/plusieurs polymères, leur production et utilisation |
| EP1975176A1 (fr) * | 2007-03-27 | 2008-10-01 | Biocompatibles UK Limited | Nouveaux peptides à fusion GLP-1, leur production et utilisation |
| EP2163243A1 (fr) * | 2008-09-12 | 2010-03-17 | Biocompatibles UK Limited | Traitement de l'infarctus du myocarde (AMI) utilisant des cellules encapsulées codant et sécrétant des peptides GLP-1 ou analogues associés |
| CN101993485B (zh) * | 2009-08-20 | 2013-04-17 | 重庆富进生物医药有限公司 | 促胰岛素分泌肽类似物同源二聚体及其用途 |
| ES2587574T3 (es) * | 2010-02-11 | 2016-10-25 | F. Hoffmann-La Roche Ag | Conjugados proteicos para la pegilación por transamidación mediada por tripsina y métodos |
| US20130225508A1 (en) * | 2010-10-01 | 2013-08-29 | Osamu Masaki | Peptide capable of binding to immunoglobulin |
| CN102766204B (zh) * | 2011-05-05 | 2014-10-15 | 天津药物研究院 | 胰高血糖素样肽-1突变体多肽及其制备方法和其应用 |
| CN102363633B (zh) * | 2011-11-16 | 2013-11-20 | 天津拓飞生物科技有限公司 | 胰高血糖素样肽-1突变体多肽及其制备方法、药物组合物和其应用 |
| EP3653649A1 (fr) | 2012-11-20 | 2020-05-20 | Mederis Diabetes, LLC | Produits pharmaceutiques peptidiques améliorés pour la résistance à l'insuline |
| CN104371019B (zh) | 2013-08-13 | 2019-09-10 | 鸿运华宁（杭州）生物医药有限公司 | 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质 |
| CN104707131A (zh) * | 2013-12-13 | 2015-06-17 | 上海建华精细生物制品有限公司 | 一种药物组合物及其制备方法和用途 |
| AU2015266854B2 (en) | 2014-05-28 | 2020-03-26 | Mederis Diabetes, Llc | Improved peptide pharmaceuticals for insulin resistance |
| DK3257524T3 (da) | 2015-02-11 | 2020-11-23 | Gmax Biopharm Llc | Stabiliseret opløsningspræparat af farmaceutisk glp-1r-antistoffusionsprotein |
| PL3393496T3 (pl) | 2015-12-23 | 2024-04-22 | The Johns Hopkins University | Długo działający agonista glp-1r jako terapia stanów neurologicznych i neurodegeneracyjnych |
| CN107818433B (zh) * | 2016-09-14 | 2022-07-05 | 菜鸟智能物流控股有限公司 | 取件方法、物流信息处理方法及装置、系统 |
| WO2018104559A1 (fr) * | 2016-12-09 | 2018-06-14 | Zealand Pharma A/S | Agonistes doubles de glp-1/glp-2 |
| WO2018104558A1 (fr) * | 2016-12-09 | 2018-06-14 | Zealand Pharma A/S | Agonistes doubles de glp-1/glp-2 acylés |
| EP3551651B1 (fr) * | 2016-12-09 | 2024-03-06 | Zealand Pharma A/S | Doubles agonistes glp-1/glp-2 acylés |
| CN108341880B (zh) * | 2017-01-23 | 2023-07-04 | 天津药物研究院有限公司 | 含有胰高血糖素样肽-1和胰高血糖素的片段类似物的嵌合多肽及其用途 |
| KR101827245B1 (ko) * | 2017-12-26 | 2018-02-08 | (주)제이유타이드 | 알라린을 주성분으로 하는 요독증 치료제 |
| JP2021509892A (ja) | 2018-01-03 | 2021-04-08 | メデリス ダイアビーティーズ，エルエルシー | Ｎａｓｈおよびその他障害の処置用の改善されたペプチド薬剤 |
| KR101903564B1 (ko) * | 2018-01-31 | 2018-11-13 | 한국지질자원연구원 | 제지공정에서 발생되는 부산물의 재활용 방법 |
| CN117964735A (zh) | 2018-04-05 | 2024-05-03 | 太阳医药工业有限公司 | 新型glp-1类似物 |
| CN115947849A (zh) | 2018-12-21 | 2023-04-11 | 江苏恒瑞医药股份有限公司 | 双特异性蛋白 |
| WO2021182928A1 (fr) * | 2020-03-12 | 2021-09-16 | 주식회사 에스엘메타젠 | Nouvelle protéine bispécifique et son utilisation |
| KR102349717B1 (ko) * | 2020-03-12 | 2022-01-11 | 주식회사 에스엘메타젠 | 신규 대사증후군 및 그와 관련된 질환 치료용 약학 조성물 |
| KR20220008788A (ko) * | 2020-07-14 | 2022-01-21 | (주)지아이이노베이션 | 글루카곤-유사 펩타이드-1 및 글루카곤-유사 펩타이드-2를 포함하는 융합 단백질 및 이의 용도 |
| CA3200351A1 (fr) * | 2020-11-27 | 2022-06-02 | Ok Cheol Jeon | Formulation orale de conjugue de materiau biologiquement actif comprenant une fraction biotine, une fraction d'acide gras ou une combinaison de celles-ci couplees a celui-ci |
| JP2023553362A (ja) * | 2020-11-27 | 2023-12-21 | ディーアンドディー ファーマテック インコーポレイテッド | ビオチン部分、脂肪酸部分またはその組合せを連結されて有する生物学的活性材料結合体 |
| CN112661862B (zh) * | 2020-12-25 | 2023-03-31 | 深圳大学 | 一种融合蛋白及其制备方法和应用 |
| CN113846124A (zh) * | 2021-09-26 | 2021-12-28 | 康霖生物科技（杭州）有限公司 | 一种用于糖代谢相关疾病基因治疗的核酸构建体 |
| CN115850438B (zh) * | 2021-12-28 | 2023-05-12 | 北京惠之衡生物科技有限公司 | 一种长效glp-1衍生物 |
| WO2024144431A1 (fr) * | 2022-12-29 | 2024-07-04 | Авва Фармасьютикалс Лтд | Nouvelle souche productrice de escherichia coli produisant une protéine hybride cbd-hs-es-glp1, et procédé de production de polypeptide glp-1 |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US586128A (en) * | 1897-07-13 | Toilet-paper holder | ||
| US4352883A (en) * | 1979-03-28 | 1982-10-05 | Damon Corporation | Encapsulation of biological material |
| ATE6548T1 (de) | 1979-10-16 | 1984-03-15 | Winfried Dr. Med. Stoecker | Vorrichtung zur durchfuehrung von mikroanalysen. |
| US4596792A (en) | 1981-09-04 | 1986-06-24 | The Regents Of The University Of California | Safe vaccine for hepatitis containing polymerized serum albumin |
| JPS5938877A (ja) | 1982-08-30 | 1984-03-02 | Musashi Eng Kk | 紙葉判別方法 |
| US4588585A (en) | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
| US4737462A (en) | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
| US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
| DD224119A1 (de) | 1983-11-07 | 1985-06-26 | Univ Schiller Jena | Temperierbarer probentraeger |
| US4599230A (en) | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
| US4599231A (en) | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
| US4608251A (en) | 1984-11-09 | 1986-08-26 | Pitman-Moore, Inc. | LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues |
| US4959314A (en) | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
| US5116943A (en) | 1985-01-18 | 1992-05-26 | Cetus Corporation | Oxidation-resistant muteins of Il-2 and other protein |
| US4601903A (en) | 1985-05-01 | 1986-07-22 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease |
| US5144139A (en) | 1985-08-05 | 1992-09-01 | Biotrack, Inc. | Capillary flow device |
| US4687529A (en) | 1985-08-30 | 1987-08-18 | Miles Laboratories, Inc. | Method of making a reagent test device containing hydrophobic barriers |
| CA1292176C (fr) | 1985-09-18 | 1991-11-19 | Joel M. Blatt | Dispositif volumetrique a orifice capillaire pour la deposition d'un echantillon liquide sur une surface reactive |
| US5017691A (en) | 1986-07-03 | 1991-05-21 | Schering Corporation | Mammalian interleukin-4 |
| US6849708B1 (en) | 1986-05-05 | 2005-02-01 | The General Hospital Corporation | Insulinotropic hormone and uses thereof |
| US4965195A (en) | 1987-10-26 | 1990-10-23 | Immunex Corp. | Interleukin-7 |
| US4904584A (en) | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
| ATE164852T1 (de) | 1990-01-24 | 1998-04-15 | Douglas I Buckley | Glp-1-analoga verwendbar in der diabetesbehandlung |
| EP0499990B1 (fr) * | 1991-02-19 | 1996-05-15 | Takeda Chemical Industries, Ltd. | Procédé pour la production des peptides sans cystéine |
| CA2062338A1 (fr) | 1991-03-15 | 1992-09-16 | Zia Yassinzadeh | Cartouche de commande electronique et methode de simulation de diagrammes de transmission lumineuse |
| GB9311147D0 (en) | 1993-05-28 | 1993-07-14 | Long Ashton Research Station | Regulation of plant growth |
| US5705483A (en) | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
| US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
| BE1008987A3 (fr) | 1995-01-06 | 1996-10-01 | Robyn Pierre | Blocs refractaires a canalisations pour sols de fours verriers et installation dans les sols de circuits de refroidissement ou de chauffage, permettant d'ameliorer le controle thermique des sols et la qualite du verre. |
| JP3643863B2 (ja) | 1995-08-09 | 2005-04-27 | アークレイ株式会社 | 液体保持具とその製造方法 |
| DE69717092T2 (de) | 1996-03-01 | 2003-07-24 | Novo Nordisk A/S, Bagsvaerd | Gebrauch einer pharmazeutischen Zusammensetzung, enthaltend ein appetitzügelndes Peptid |
| US6165739A (en) | 1996-03-13 | 2000-12-26 | Compucyte Corporation | Multiple simultaneous testing media |
| CA2262647C (fr) * | 1996-08-08 | 2007-12-04 | Amylin Pharmaceuticals, Inc. | Methodes de regulation de la motilite gastro-intestinale |
| HU227021B1 (en) * | 1996-08-30 | 2010-05-28 | Novo Nordisk As | Glp-1 derivatives |
| JP2001504105A (ja) | 1996-11-12 | 2001-03-27 | ノボ ノルディスク アクティーゼルスカブ | Ｇｌｐ―１ペプチドの利用 |
| CA2318376A1 (fr) | 1998-01-12 | 1999-07-15 | Betagene, Inc. | Compositions et procedes regulant la secretion de lignees de cellules neuroendocrines |
| AU2988899A (en) | 1998-03-06 | 1999-09-20 | Altea Technologies, Inc. | Integrated tissue poration, fluid harvesting and analysis device, and method therefor |
| EP1062229A1 (fr) * | 1998-03-09 | 2000-12-27 | Zealand Pharmaceuticals A/S | Conjugues peptidiques pharmacologiquement actifs ayant une tendance reduite a l'hydrolyse enzymatique |
| WO1999053064A2 (fr) | 1998-04-13 | 1999-10-21 | Modex Therapeutiques, S.A. | Techniques d'administration de glp-1 |
| US7259136B2 (en) | 1999-04-30 | 2007-08-21 | Amylin Pharmaceuticals, Inc. | Compositions and methods for treating peripheral vascular disease |
| US6267954B1 (en) | 1999-11-24 | 2001-07-31 | Universite De Paris V Rene-Descartes | Intraocular transplantation of encapsulated cells |
| US6706159B2 (en) | 2000-03-02 | 2004-03-16 | Diabetes Diagnostics | Combined lancet and electrochemical analyte-testing apparatus |
| DE60114996T2 (de) | 2000-03-08 | 2006-08-10 | Novo Nordisk A/S | Senkung des serum cholesterols |
| DE10039643A1 (de) * | 2000-08-14 | 2002-02-28 | Max Planck Gesellschaft | Funktionalisierte Perylentetracarbonsäurediimide |
| WO2002046227A2 (fr) | 2000-12-07 | 2002-06-13 | Eli Lilly And Company | Proteines hybrides glp-1 |
| US6821485B2 (en) | 2001-02-09 | 2004-11-23 | Wisconsin Alumni Research Foundation | Method and structure for microfluidic flow guiding |
| US20020183253A1 (en) | 2001-02-22 | 2002-12-05 | Brazzell Romulus Kimbro | Method of treating ocular neovascularization |
| US20030034147A1 (en) | 2001-05-31 | 2003-02-20 | Houck Glenn M. | Apparatus which eliminates the need for idling by trucks |
| DE60224284T2 (de) | 2001-06-28 | 2008-12-18 | Novo Nordisk A/S | Stabile formulierung von modifiziertem glp-1 |
| CN1363654A (zh) | 2001-07-19 | 2002-08-14 | 上海华谊生物技术有限公司 | 生产促胰岛素分泌肽glp－1(7－36)的基因工程菌以及生产glp－1(7－36)的方法 |
| WO2003010305A1 (fr) | 2001-07-27 | 2003-02-06 | Arhus Amt | Cellules souches immortalisées |
| ATE408414T1 (de) | 2001-07-31 | 2008-10-15 | Us Gov Health & Human Serv | Glp 1 exendin 4 peptidanaloga und deren verwendungen |
| US20040143104A1 (en) | 2001-08-08 | 2004-07-22 | Wadsworth Samuel C. | Methods of treating diabetes and other blood sugar disorders |
| JP2005508895A (ja) | 2001-08-28 | 2005-04-07 | イーライ・リリー・アンド・カンパニー | Ｇｌｐ−１および基礎インスリンの予備混合物 |
| US7176278B2 (en) | 2001-08-30 | 2007-02-13 | Biorexis Technology, Inc. | Modified transferrin fusion proteins |
| US7166208B2 (en) | 2004-03-03 | 2007-01-23 | Stephen Eliot Zweig | Apoenzyme reactivation electrochemical detection method and assay |
| EP1790353A1 (fr) | 2001-12-29 | 2007-05-30 | Novo Nordisk A/S | Utilisation combinée d'un composé GLP-1 et d'un modulateur de complications diabétiques tardives |
| EP1585959A4 (fr) | 2002-01-08 | 2007-11-14 | Lilly Co Eli | Analogues de peptide-1 de type glucagon d'extension |
| GB2388898B (en) | 2002-04-02 | 2005-10-05 | Inverness Medical Ltd | Integrated sample testing meter |
| US20030191056A1 (en) * | 2002-04-04 | 2003-10-09 | Kenneth Walker | Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins |
| US20030143113A2 (en) | 2002-05-09 | 2003-07-31 | Lifescan, Inc. | Physiological sample collection devices and methods of using the same |
| EP1539210A4 (fr) | 2002-09-06 | 2006-06-07 | Bayer Pharmaceuticals Corp | Agonistes modifies du recepteur glp-1 et leurs procedes pharmacologiques d'utilisation |
| WO2004078195A1 (fr) * | 2003-03-07 | 2004-09-16 | Ajinomoto Co., Inc. | Agent de conversion de cellule intestinale en cellule produisant de l'insuline et remede pour le diabete |
| US6969166B2 (en) | 2003-05-29 | 2005-11-29 | 3M Innovative Properties Company | Method for modifying the surface of a substrate |
| US7057116B2 (en) | 2003-06-02 | 2006-06-06 | Intel Corporation | Selective reference plane bridge(s) on folded package |
| PT1641823E (pt) * | 2003-06-12 | 2011-11-08 | Lilly Co Eli | Proteínas de fusão de análogos de glp-1 |
| EP1498143A1 (fr) | 2003-07-18 | 2005-01-19 | Aventis Pharma S.A. | Formulations auto-émulsifiantes et auto-microémulsifiantes pour l'administration orale de taxoides |
| WO2005014035A2 (fr) | 2003-08-08 | 2005-02-17 | Novo Nordisk Health Care Ag | Utilisation de galactose oxydase pour la conjugaison chimique selective de molecules d'extraction a des proteines d'interet therapeutique |
| JP2007508250A (ja) | 2003-10-10 | 2007-04-05 | ノボ ノルディスク アクティーゼルスカブ | 持続性放出製剤における長期作用性分子 |
| BRPI0417684A (pt) * | 2003-12-18 | 2007-03-20 | Novo Nordisk As | composto, composição farmacêutica, e, uso de um composto |
| WO2005072216A2 (fr) | 2004-01-20 | 2005-08-11 | The Curators Of The University Of Missouri | Viscosimetres moleculaires de biofluides sir support a usage un vitro et un vivo |
| CA2849552A1 (fr) | 2004-02-11 | 2005-08-25 | Amylin Pharmaceuticals, Llc | Polypeptides hybrides presentant des proprietes pouvant etre choisies |
| WO2005098431A1 (fr) | 2004-03-05 | 2005-10-20 | Egomedical Swiss Ag | Systeme de test d'analyte permettant de determiner la concentration d'un analyte dans un fluide physiologique |
| BRPI0509528A (pt) | 2004-03-31 | 2007-08-07 | Centocor Inc | corpos imitação de glp-1 humana, composições, processos e usos |
| WO2006010143A2 (fr) * | 2004-07-13 | 2006-01-26 | Neose Technologies, Inc. | Remodelage de peg ramifie et glycosylation de peptide-1 semblable a glucagon [glp-1] |
| MX2007001770A (es) | 2004-08-13 | 2007-08-07 | Egomedical Technologies Ag | Sistema de prueba de analitos para determinar la concentracion de un analito en un fluido fisiologico o acuoso. |
| US7442682B2 (en) | 2004-10-19 | 2008-10-28 | Nitto Denko Corporation | Transepithelial delivery of peptides with incretin hormone activities |
| EP1909823A2 (fr) | 2005-07-29 | 2008-04-16 | Amprotein Corporation | Agents therapeutiques chimeriques |
| EP1767545B1 (fr) | 2005-09-22 | 2009-11-11 | Biocompatibles UK Limited | Polypeptides de fusion de glp-1 (peptide 1 de type glucagon) ayant une resistance accrue a la peptidase |
| EP1854455B1 (fr) | 2006-05-10 | 2009-10-07 | Biocompatibles UK Limited | Microcapsules sphériques contenant des peptides du type GLP-1, leur production et leur utilisation |
| EP1972349A1 (fr) | 2007-03-21 | 2008-09-24 | Biocompatibles UK Limited | Peptides à fusion GLP-1 associée à un/plusieurs polymères, leur production et utilisation |
| EP1975176A1 (fr) | 2007-03-27 | 2008-10-01 | Biocompatibles UK Limited | Nouveaux peptides à fusion GLP-1, leur production et utilisation |
| EP2163243A1 (fr) | 2008-09-12 | 2010-03-17 | Biocompatibles UK Limited | Traitement de l'infarctus du myocarde (AMI) utilisant des cellules encapsulées codant et sécrétant des peptides GLP-1 ou analogues associés |
-
2005
- 2005-09-22 EP EP05020718A patent/EP1767545B1/fr active Active
- 2005-09-22 EP EP08021837A patent/EP2045265B1/fr active Active
- 2005-09-22 PT PT05020718T patent/PT1767545E/pt unknown
- 2005-09-22 DK DK05020718.2T patent/DK1767545T3/da active
- 2005-09-22 AT AT05020718T patent/ATE448247T1/de active
- 2005-09-22 PL PL05020718T patent/PL1767545T3/pl unknown
- 2005-09-22 ES ES05020718T patent/ES2336575T3/es active Active
- 2005-09-22 ES ES08021837T patent/ES2397289T3/es active Active
- 2005-09-22 RS RSP-2010/0039A patent/RS51319B/sr unknown
- 2005-09-22 SI SI200530887T patent/SI1767545T1/sl unknown
- 2005-09-22 DE DE602005017628T patent/DE602005017628D1/de active Active
-
2006
- 2006-09-22 EP EP10009718A patent/EP2261245A1/fr not_active Withdrawn
- 2006-09-22 KR KR1020087009543A patent/KR20080064840A/ko not_active Application Discontinuation
- 2006-09-22 EP EP06792228A patent/EP1926748B1/fr not_active Not-in-force
- 2006-09-22 US US11/991,562 patent/US8431533B2/en not_active Expired - Fee Related
- 2006-09-22 CN CNA2006800350367A patent/CN101273058A/zh active Pending
- 2006-09-22 EA EA200800699A patent/EA013796B1/ru not_active IP Right Cessation
- 2006-09-22 CA CA002619053A patent/CA2619053A1/fr not_active Abandoned
- 2006-09-22 EP EP09014513A patent/EP2174952A3/fr not_active Withdrawn
- 2006-09-22 BR BRPI0616107-3A patent/BRPI0616107A2/pt not_active IP Right Cessation
- 2006-09-22 JP JP2008531616A patent/JP5222729B2/ja not_active Expired - Fee Related
- 2006-09-22 AU AU2006299134A patent/AU2006299134B2/en not_active Ceased
- 2006-09-22 WO PCT/EP2006/009226 patent/WO2007039140A1/fr active Application Filing
- 2006-09-22 SG SG201006921-9A patent/SG165414A1/en unknown
- 2006-09-22 ES ES06792228T patent/ES2394218T3/es active Active
- 2006-09-22 ZA ZA200803488A patent/ZA200803488B/xx unknown
-
2008
- 2008-01-21 IL IL188904A patent/IL188904A0/en unknown
-
2010
- 2010-02-02 HR HR20100062T patent/HRP20100062T1/hr unknown
- 2010-02-11 CY CY20101100139T patent/CY1109778T1/el unknown
-
2012
- 2012-05-29 US US13/482,354 patent/US8853159B2/en not_active Expired - Fee Related
-
2013
- 2013-01-25 JP JP2013012558A patent/JP2013099352A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL188904A0 (en) | Glp-1 (glucagon-like peptide-1) fusion polypeptides with increased peptidase resistance | |
| WO2008116648A3 (fr) | Nouveaux peptides de fusion glp-1, leur production et leur utilisation | |
| US20190085043A1 (en) | Fusion proteins for treating a metabolic syndrome | |
| JP5580784B2 (ja) | 選択可能な特性を有するハイブリッドポリペプチド | |
| WO2003033671A3 (fr) | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions | |
| JP2019085420A (ja) | エラスチン様ペプチドを含む治療剤 | |
| TW200716679A (en) | N-terminally modified GLP-1 receptor modulators | |
| EP2390264A1 (fr) | Analogues de GIP et polypeptides hybrides de GIP aux propriétés sélectionnables | |
| WO2006014287A8 (fr) | Modulateurs de glp-1 humain 1 et leur utilisation pour le traitement du diabète et de conditions connexes | |
| WO2007140284A3 (fr) | Modulateurs des récepteurs de glp-1 modifiés en n-terminal | |
| EP2070946A3 (fr) | Invention concernant GLP-1 et l'exendine | |
| US20030232761A1 (en) | Novel analogues of glucose-dependent insulinotropic polypeptide | |
| WO2006017688A3 (fr) | Polythérapie basée sur l’utilisation de protéines hybrides de transferrine contenant du glp-1 | |
| JP2016188225A (ja) | 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド | |
| WO2006086727A3 (fr) | Traitement des diabetes au moyen de secretagogues du glucagon-like peptide 1 | |
| JP2004509079A5 (fr) | ||
| WO2006121860A3 (fr) | Agonistes vis-a-vis du recepteur peptidique de type glucagon 1 (glp-1) et procedes pharmacologiques d'utilisation | |
| AR022368A1 (es) | Procedimiento para administrar peptidos insulinotropicos | |
| US20110288001A1 (en) | Biologically active proteins activatable by peptidase | |
| Linderoth et al. | GLP‐1 Receptor Agonists for the Treatment of Type 2 Diabetes and Obesity | |
| Oskola et al. | Angioprotektivnoe properties lowering drugs from the group of inhibitors of dipeptidyl peptidase-4 |